REAGILA: An Atypical Antipsychotic Used in the Treatment of Schizophrenia and Manic or Mixed Episodes of Bipolar Disorder
DUBLIN, Dec. 8, 2023 /PRNewswire/ — The “REAGILA Drug Insight and Market Forecast – 2032” drug pipelines has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about REAGILA for schizophrenia in the seven major markets. A detailed picture of the REAGILA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and … Read more